260660 — Korea Arlico Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual income statement for Korea Arlico Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	—	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	140,157	167,737	187,155	190,436	201,204
Cost of Revenue
Gross Profit	87,529	106,924	110,179	99,796	104,299
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	135,363	157,873	184,082	195,522	200,214
Operating Profit	4,794	9,864	3,073	-5,086	989
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,605	8,391	3,476	-6,174	-1,092
Provision for Income Taxes
Net Income After Taxes	4,930	8,034	3,061	-5,358	-605
Net Income Before Extraordinary Items
Net Income	4,930	8,034	3,061	-5,358	-605
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	4,930	8,720	1,755	-5,358	-605
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	271	550	104	-377	-37.8
Dividends per Share